Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 2.78 USD 2.96% Market Closed
Market Cap: 477.1m USD

EV/EBIT
Enterprise Value to EBIT

-3.1
Current
-4.7
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.1
=
Enterprise Value
282.1m USD
/
EBIT
-89.7m USD
Market Cap EV/EBIT
US
Savara Inc
NASDAQ:SVRA
474.9m USD -3.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -209 659.2
US
Abbvie Inc
NYSE:ABBV
361.9B USD 25.3
US
Amgen Inc
NASDAQ:AMGN
165.1B USD 28.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.4B USD 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.7B USD 27.3
US
Epizyme Inc
F:EPE
94.1B EUR -518.5
AU
CSL Ltd
ASX:CSL
122.4B AUD 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
70.3B USD 11.5
US
Seagen Inc
F:SGT
39.3B EUR -55
NL
argenx SE
XBRU:ARGX
33B EUR -2 323.6
EBIT Growth EV/EBIT to Growth
US
Savara Inc
NASDAQ:SVRA
Average EV/EBIT: 21.5
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 659.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.3
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.3
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 323.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2.8
2-Years Forward
EV/EBIT
-2.6
3-Years Forward
EV/EBIT
-4.6